Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants - Scorecard - MDSpire
Advertisement
Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants
Clinical Scorecard: Evaluation of Safety and Immune Response in Infants Receiving a Three-Dose Series of a Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine
At a Glance
Category
Detail
Condition
Pertussis
Key Mechanisms
Evaluation of immune response and safety of DTcP vaccine compared to DTaP vaccines.
Target Population
Infants aged 3 months.
Care Setting
Clinical trial setting in Henan Province, China.
Key Highlights
DTcP vaccine demonstrated non-inferiority and superiority over co-purified DTaP for anti-PT and anti-FHA immunogenicity.
DTcP achieved a 98.16% seroconversion rate for anti-FHA.
Both DTcP and co-purified DTaP had lower adverse reaction rates compared to DTaP-IPV-Hib.
Guideline-Based Recommendations
Diagnosis
Monitor for pertussis symptoms in infants, especially in the context of recent outbreaks.
Management
Consider transitioning to DTcP vaccine in immunization programs to enhance immune response.
Monitoring & Follow-up
Assess safety and immunogenicity post-vaccination in infants.
Risks
Be aware of potential adverse reactions associated with pertussis vaccines.
Patient & Prescribing Data
Healthy infants aged 3 months without prior vaccinations.
DTcP vaccine shows improved immunogenicity and safety profile.
Clinical Best Practices
Follow the Expanded Program on Immunization (EPI) schedule for infant vaccinations.
Ensure informed consent is obtained from parents or guardians before vaccination.
